formerly of Eli Lilly and Company
Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis
Version of Record online: 2 DEC 2013
© 2013 British Association of Dermatologists
British Journal of Dermatology
Volume 169, Issue 6, pages 1337–1341, December 2013
How to Cite
Zhu, B., Edson-Heredia, E., Cameron, G.S., Shen, W., Erickson, J., Shrom, D., Wang, P., Banerjee, S. and Gordon, K.B. (2013), Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis. British Journal of Dermatology, 169: 1337–1341. doi: 10.1111/bjd.12610
Funding sources Eli Lilly and Company.
Conflicts of interest B.Z., E.E.-H., G.S.C., W.S, J.E., D.S., P.W., and S.B. are all full-time employees of, and own stock in, Eli Lilly and Company. K.B.G. has received research support from Eli Lilly and Company, Amgen, Janssen Pharmaceuticals, Merck and Celgene Corporation, and honoraria from Eli Lilly and Company, Amgen, Pfizer, Janssen, Novartis, AbbVie and Celgene Corporation.
The primary results of this phase II study have previously been published (Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366:1190–9).
- Issue online: 2 DEC 2013
- Version of Record online: 2 DEC 2013
- Accepted manuscript online: 6 SEP 2013 02:14AM EST
- Manuscript Accepted: 28 AUG 2013
- Jiaying Guo of inVentiv Health Clinical
|bjd12610-sup-0001-TableS1.docx||Word document||14K||Table S1. Sensitivity, specificity, positive predictive value and negative predictive value of Psoriasis Area and Severity Index (PASI) percentage improvement at weeks 4 and 6 for predicting PASI 75 responses at week 12 for the all-dose group (n = 114) and the high-dose group (n = 57).|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.